A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.
Also called NCT05813912
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 148 participants
- Sponsor
- Registry
-
NCT05813912 -
2022-002847-24
-
- Other papers using this trial's data
- Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Czechia, Malaysia, Poland, Serbia, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT05813912. Allocation not applicable; no masking; primary purpose treatment. Start 2023-09-22 (actual); primary completion 2025-04-14 (actual). Results posted on 2026-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Icodec
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05813912- Content hash
07370c823b20bad676bfe06aca4300b1fa879ef445b74310b2c60d0dacf832de